快速訂購

B7-H3/CD276 Immune Checkpoint Inhibitors

B7-H3/CD276 immune checkpoint inhibitors are drugs used to target B7-H3/CD276 molecule, which is a B7 family immune checkpoint protein. B7-H3/CD276 do not yet have defined receptor, but mouse knockout experiments support an immune inhibitory role for it. Blockage of this checkpoint by B7-H3/CD276 immune checkpoint inhibitor can enhance anti-tumour immunity. The B7-H3/CD276 immune checkpoint inhibitor MGA271 have been developped to cue various cancers: Melanoma, non small cell lung cancer (NSCLC)……

B7-H3/CD276 Immune Checkpoint Inhibitors: Developments

Disease B7-H3/CD276 immune checkpoint inhibitors research development
Melanoma MGA271 —— The purpose of this study is to evaluate the safety of MGA271 (B7-H3/CD276 immune checkpoint inhibitors drug) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing melanoma (NCT02381314).
squamous cell carcinoma of the head and neck (SCCHN) MGA271 —— The purpose of this study is to evaluate the safety of MGA271 (B7-H3/CD276 immune checkpoint inhibitors drug) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing squamous cell carcinoma of the head and neck (NCT02381314).
non small cell lung cancer (NSCLC) MGA271 —— The purpose of this study is to evaluate the safety of MGA271 (B7-H3/CD276 immune checkpoint inhibitors drug) in combination with Yervoy (ipilimumab) when given to patients with B7-H3-expressing non small cell lung cancer (NSCLC) (NCT02381314).
Cervical cancer Ipilimumab (Yervoy®) —— a CTLA-4/CD152 immune checkpoint inhibitors drug made by Bristol-Myers Squibb, is being tested in two clinical trials for patients with cervical cancer: a phase II study of ipilimumab for HPV+ cervical cancer that is metastatic or recurrent (NCT01693783), and a phase I study of chemoradiation followed by ipilimumab for patients with locally advanced cervical cancer (NCT01711515).
Tremelimumab—— a CTLA-4/CD152 immune checkpoint inhibitors drug, is being tested in combination MEDI4736, an anti-PD-L1 antibody,, in a phase I trial for patients with six kinds of cancer, including cervical cancer (NCT01975831).
Kidney Cancer MGA217 —— a phase I study to test MGA217, a B7-H3/CD276 immune checkpoint inhibitors drug, is launched in patients with refractory cancer, including renal cell cancer (NCT01391143).

B7-H3/CD276 Immune Checkpoint Inhibitors: Relatives

PD1/PDCD1/CD279 immune checkpoint inhibitors  
PD-L1/B7-H1/CD274 immune checkpoint inhibitors  
CTLA-4/CD152 immune checkpoint inhibitors  
Indoleamine 2,3‑dioxygenase/IDO immune checkpoint inhibitors  
KIR immune checkpoint inhibitors  
LAG3 / CD223 immune checkpoint inhibitors  
請注意:所有產品都是“僅用於科研,而不能用於診斷或治療用途”